

SUPPLEMENT DATED 16 AUGUST 2021

**Commonwealth Bank Australia**

Commonwealth Bank of Australia, A.B.N. 48 123 123 124



Incorporated in Australia with limited liability

**U.S.\$70,000,000,000\***

## **Euro Medium Term Note Programme**

*\*Combined programme limit for the Euro Medium Term Note Programme of ASB Finance Limited and Commonwealth Bank of Australia. This Supplement relates to Notes to be issued under such programme by Commonwealth Bank of Australia only.*

This supplement (the “**Supplement**”) comprises a supplement for Commonwealth Bank of Australia (the “**Issuer**”) to the Programme Circular dated 2 July 2021 (the “**Programme Circular**”). The Programme Circular is a base prospectus for the purposes of the UK Prospectus Regulation prepared in connection with the Euro Medium Term Note Programme (the “**Programme**”) established by the Issuer. This Supplement constitutes a supplement to the Programme Circular for the purposes of Article 23 of the UK Prospectus Regulation. When used in this Supplement, “**UK Prospectus Regulation**” means Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

Terms defined in the Programme Circular have the same meaning when used in this Supplement. This Supplement is supplemental to, and should be read in conjunction with, the Programme Circular and any other supplements to the Programme Circular issued by the Issuer. This Supplement will be published on the website of the Issuer at <https://www.commbank.com.au/about-us/investors/emtn-programme.html>. A copy of the Annual Report is available on the website of the Issuer at [https://www.commbank.com.au/content/dam/commbank-assets/about-us/2021-08/2021-annual-report\\_spreads.pdf](https://www.commbank.com.au/content/dam/commbank-assets/about-us/2021-08/2021-annual-report_spreads.pdf).

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer the information contained in this Supplement is in accordance with the facts and the Supplement makes no omission likely to affect their import.

The purpose of this Supplement is to (i) incorporate by reference specified pages of the Annual Report into the Programme Circular; and (ii) confirm that since 30 June 2021, the last day of the financial period in respect of which the most recent audited financial statements have been published, there has been no significant change in the financial performance or financial position of the Issuer and its subsidiaries, taken as a whole, and that since 30 June 2021, the last day of the financial period in respect of which the most recent audited financial statements have been published there has been no material adverse change in the prospects of the Issuer and its subsidiaries, taken as a whole.

On 11 August 2021, the Issuer published its Annual Report (the “**Annual Report**”) for the financial year ended 30 June 2021, which includes its audited consolidated and non-consolidated annual financial statements (including the auditor's report thereon) for the financial year ended 30 June 2021. A copy of the Annual Report has been filed with the UK Financial Conduct Authority.

Accordingly, the audited consolidated and non-consolidated annual financial statements for the financial year ended 30 June 2021 and the auditor's report (set out on pages 114 to 269 (inclusive) and on pages 271 to 278 (inclusive), respectively, of the Annual Report) of the Issuer shall be deemed to be incorporated in, and form

part of, the Programme Circular. The non-incorporated parts of the Annual Report are either not relevant for the investor or are covered elsewhere in the Programme Circular.

Since 30 June 2021, there has been no significant change in the financial performance or financial position of the Issuer and its subsidiaries, taken as a whole, nor, since 30 June 2021, the last day of the financial period in respect of which the most recent audited financial statements have been published, save as disclosed in the Programme Circular in the risk factors entitled "*The Group's results could be adversely impacted by key strategic risks arising from changes in the Group's external and internal operating environment*" and "*The COVID-19 pandemic and future outbreaks of other communicable diseases or pandemics may materially and adversely affect the business, results of operations, financial condition and prospects of the Group*" on pages 11 – 13 of the Programme Circular and the sections entitled "*Recent Developments – Other Developments – APRA and the RBNZ developments in response to COVID-19 support*" on page 109 of the Programme Circular, there has been no material adverse change in the prospects of the Issuer and its subsidiaries, taken as a whole.

If documents which are incorporated by reference themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the UK Prospectus Regulation except where such information or other documents are specifically incorporated by reference.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Programme Circular by this Supplement and (b) any other statement in or incorporated by reference in the Programme Circular, the statements in (a) above will prevail.

Save as disclosed in this Supplement and any other supplement to the Programme Circular previously issued, there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Programme Circular since the publication of the Programme Circular.